642 Individualized Treatment Duration With Peginterferon-Alfa-2b and Ribavirin for 24, 30 or 36 Weeks in HCV Genotype1-Infected Patients With Undetectable HCV-Rna Early During Therapy (Indiv-2 Study)

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis

“…Among 17 references identified, 10 studies were excluded for the following reasons: one was retrospective [18], 2 were not randomized and used a historical control group [10,19], 2 RCTs had a study design which did not enable comparison of shortened therapy to 48 weeks in patients with rapid viral decline [20,21], one used non-pegylated interferon [22], and 4 studies [23][24][25][26] because the last publications of those trials were available [7][8][9]27].…”

“…After inclusion in the core group of 2 studies using historical control groups [10,19], the SVR rate was still lower in the shortened treatment group (data not shown). In spite of similar end-oftreatment virological response rates, the relapse rate was significantly higher in the shorter treatment duration group.…”